SELECTED IMPORTANT SAFETY INFORMATION: You should not use Jivi if you are allergic to rodents (like mice and hamsters) or to any ingredients in Jivi. CONTINUE READING BELOW

Zach Castillo

Confident. Lifelong Texan. Camp counselor.

For those living with hemophilia A, a strong family support system can be key. For Zach Castillo, an uncle with his same condition gave him just that – and helped guide him on his journey. Check out the videos below to meet Zach and discover his journey to Jivi.

Video title

Watch More From Zach

Video title

YYMMDD Author/Uploaded by

Video title

YYMMDD Author/Uploaded by

Meet Zach or other patients and caregivers at a live speaking event in your area. Hear their unique stories and connect one-on-one.

Get in touch with your Rep
Zach Castillo as a young boy and Zach as a child sitting on his Uncle John’s lap
Graphic with text saying At the end of the day, after all this time and all these experiences, now I’m able to say that I’m no longer that apprehensive kid, unsure about his condition. It’s been a journey.
Zach standing on rocks posing by the water. Zach posing with his mom by a Christmas tree.
Graphic with text saying My uncle really emphasized the need for me to stay on top of my medicine to help control my bleeds. He wanted to make sure that I was taking care of myself. At times he was stern – he would tell me that if I didn’t take care of myself, that no one was obligated to. I listened. It really put things into perspective for me to hear him - and see him.
Graphic with text saying For someone like me who’s always on the go, the possibility to eventually infuse every 5 days, based on my bleeding episodes and consultation with my doctor, was a big deciding factor in making the switch.
Zach posing outside the United States Capitol building.

Interested in learning more about Jivi, or want to find out how to schedule a live My Journey to Jivi event in your area?

INDICATIONS

Jivi is an injectable medicine used to replace clotting factor (Factor VIII or antihemophilic factor) that is missing in people with hemophilia A.

Jivi is used to treat and control bleeding in previously treated adults and adolescents (12 years of age and older) with hemophilia A. Your healthcare provider may also give you Jivi when you have surgery. Jivi can reduce the number of bleeding episodes in adults and adolescents with hemophilia A when used regularly (prophylaxis).

Jivi is not for use in children below 12 years of age or in previously untreated patients.

Jivi is not used to treat von Willebrand disease.

IMPORTANT SAFETY INFORMATION

You should not use Jivi if you are allergic to rodents (like mice and hamsters) or to any ingredients in Jivi.

Tell your healthcare provider about all of your medical conditions that you have or had.

Tell your healthcare provider if you have been told that you have inhibitors to Factor VIII.

Allergic reactions may occur with Jivi. Call your healthcare provider right away and stop treatment if you get tightness of the chest or throat, dizziness, decrease in blood pressure, or nausea.

Allergic reactions to polyethylene glycol (PEG), a component of Jivi, are possible.

Your body can also make antibodies, called “inhibitors,” against Jivi, which may stop Jivi from working properly. Consult your healthcare provider to make sure you are carefully monitored with blood tests for the development of inhibitors to Factor VIII.

If your bleeding is not being controlled with your usual dose of Jivi, consult your doctor immediately. You may have developed Factor VIII inhibitors or antibodies to PEG and your doctor may carry out tests to confirm this.

The common side effects of Jivi are headache, cough, nausea, and fever.

These are not all the possible side effects with Jivi. Tell your healthcare provider about any side effect that bothers you or that does not go away.

For additional important risk and use information, please see the full Prescribing Information.

References: 1. Jivi ® Prescribing Information. Whippany, NJ: Bayer LLC; 2018. 2. Data on file. Tx Review 0918. Bayer; 2018.